Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Xolair
| Field | Information |
|---|---|
| Medication Name | Xolair |
| Generic Name | Omalizumab |
| Boxed/Label Warning | Anaphylaxis (severe allergic reaction) can occur up to several days after receiving a Xolair injection. |
| Purpose | Treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU), and nasal polyps in certain patients. |
| Mechanism of Action | Binds to immunoglobulin E (IgE), reducing free IgE levels and preventing the activation of mast cells and basophils. |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 150 mg/mL |
| Dosage Frequency | Every 2 or 4 weeks, as determined by IgE level and body weight. |
| Common Side Effects | Injection site reactions (pain, redness, swelling, itching), upper respiratory infections, headache, sinusitis, sore throat. |
| Serious Side Effects | Anaphylaxis, malignancy (cancer), Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis), parasitic infection. |
| Drug Interactions | No significant drug interactions have been identified. |
| Important Notes | Administered by a healthcare professional in a healthcare setting. Patients should be monitored for anaphylaxis after each injection. Not for use in treating acute asthma attacks or other acute allergic conditions. |
| Storage | Refrigerate at 2° to 8°C (36° to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately to reschedule your injection. |
| Alternatives | Dupixent (dupilumab), Nucala (mepolizumab), Fasenra (benralizumab), Tezspire (tezepelumab) |
Xolair Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Dupixent (dupilumab) | IL-4 receptor alpha subunit antagonist | Used for asthma and other allergic conditions. |
| Nucala (mepolizumab) | IL-5 antagonist | Reduces eosinophils in asthma. |
| Fasenra (benralizumab) | IL-5 receptor alpha subunit antagonist | Reduces eosinophils in asthma. |
| Tezspire (tezepelumab) | TSLP blocker | Blocks TSLP, an upstream mediator of inflammation. |
Xolair Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection site reactions (pain, redness, swelling, itching) | Anaphylaxis (severe allergic reaction) |
| Upper respiratory infections | Malignancy (cancer) |
| Headache | Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis) |
| Sinusitis | Parasitic infection |
Xolair Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Allergic Asthma | Dose determined by IgE level and body weight | Every 2 or 4 weeks | Administered subcutaneously by a healthcare provider. Observe patient for anaphylaxis. |
| Chronic Idiopathic Urticaria (CIU) | 150 mg or 300 mg | Every 4 weeks | Administered subcutaneously by a healthcare provider. Observe patient for anaphylaxis. |
| Nasal Polyps | 75 mg to 600 mg | Every 2 or 4 weeks | Administered subcutaneously by a healthcare provider. Observe patient for anaphylaxis. |
